Press Releases.

Investor Menu

Investor Relations

Overview
News
Press Releases Media Coverage
Presentation & Events
Presentations Events
Shareholder Proxy FAQ
Governance
Directors Leadership Scientific Advisory Board Manufacturing and Quality Advisory Board Committee Composition Documents & Charters
Stock Information
Stock Quote & Chart Analyst Coverage Ownership Profile
Financials & Filings
SEC Filings Annual Reports and Proxies Quarterly Results
Investor Resources
Investor FAQs Email Alerts Contact IR

Search

Year

May 09, 2022

PDF Version

Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1 st Quarter with $157.0 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif. , May 09, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc.

April 14, 2022

PDF Version

Vaxart to Present at World Vaccine Congress Washington 2022 on April 20

SOUTH SAN FRANCISCO, Calif. , April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker , SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET .

February 24, 2022

PDF Version

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year Ended 2021 with $182.7 million in cash, cash equivalents and

February 24, 2022

PDF Version

Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs Vaxart’s S-only candidate induced a

February 14, 2022

PDF Version

Vaxart Appoints Edward Berg as Senior Vice President and General Counsel

Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced the appointment of Edward B. Berg as the Company's first in-house General Counsel, effective

January 04, 2022

PDF Version

Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference

SOUTH SAN FRANCISCO, Calif. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu , President and Chief Executive Officer, Dr. Sean Tucker , SVP and Chief Scientific Officer, and Dr. James Cummings , Chief Medical Officer, will participate in a virtual

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Welcome
Tech
Mission
Investors

LinkedIn
Twitter
Youtube

Scroll to top